May 6, 2024 8:00 am EDT Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Apr 11, 2024 10:03 am EDT First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Apr 1, 2024 7:14 am EDT Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Mar 26, 2024 8:00 am EDT Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Mar 8, 2024 8:00 am EST Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Feb 15, 2024 4:10 pm EST Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)